Table 1. Overview study populations.
| Country | Year | Population | Age range or minimum age (years) | Gametocyte screening | Gametocyte prevalence in selected individuals (n/N) | Median gametocyte density (IQR) |
| Cameroon-1 [30] | 1993 | Clinic attendees | 4–63 | 1000 WBC | 97.6 (121/124) | 156 (72–400) |
| Cameroon-2 [23] | 1996–7 | Survey participants | ≥5 | 3000 WBC | 82.6 (38/46) | 23 (6–70) |
| Cameroon-3 [29] | 1996 | Clinic attendees | 1–63 | 1000 WBC | 98.2 (55/56) | 296 (88–536) |
| Cameroon-4 [33] | 1996–8 | Survey participants | ≥2 | 3000 WBC | 95.8 (69/72) | 36 (12–128) |
| Cameroon-5 (Gouagna et al., unpublished) | 1998 | Survey participants & clinic attendees | ≥2 | 500 WBC | 100 (22/22) | 275 (78–456) |
| Cameroon-6 (Morlais et al., unpublished) | 2011 | Survey participants | 5–11 | 1000 WBC | 100 (25/25) | 24 (21–36) |
| Mali [25], [34] | 1996–8 | Survey participants | 4–18 | 300 WBC | 97.1 (68/70) | 100 (50–225) |
| Papua New Guinea [26] | 1983–1985 | Survey participants & clinic attendees | 0.5–≥20 | 100 fields | NA | NA |
| Senegal [27] | 1998 | Survey participants | 6–57 | 200 fields | 100 (60/60) | 269 (91–562) |
| The Gambia [17], [28], [38], [39] | 1998–2000 | Confirmed malaria cases | 0.5–17 | 100 fields | 85.1 (292/343) | 56 (15–280) |
Year = year of data collection; Survey participants = participants of cross-sectional surveys, largely asymptomatic population, were screened for gametocytes; clinic attendees = individuals with suspected malaria were screened for gametocytes; n = number of gametocyte positive individuals; N = number of people screened for gametocytes among the study population; gametocyte density = median density/µL for gametocyte positive individuals only; IQR = interquartile range (25th and 75th percentile), WBC = white blood cells.